04th week of 2022 patent applcation highlights part 11 |
Patent application number | Title | Published |
20220023362 | PHARMACEUTICAL COMPOSITION CONTAINING AUCUBA JAPONICA EXTRACT FOR PREVENTING OR TREATING MACULAR DEGENERATION | 2022-01-27 |
20220023363 | SYSTEMS AND COMPOSITIONS FOR DELIVERING ACTIVE PLANT COMPONENTS | 2022-01-27 |
20220023364 | COMPOSITION FOR ALLEVIATING FATIGUE OR ENHANCING EXERCISE CAPABILITY COMPRISING ANGELICA GIGAS EXTRACT, CNIDIUM OFFICINALE EXTRACT, AND PAEONIA LACTIFLORA EXTRACT | 2022-01-27 |
20220023365 | COMPOSITIONS FOR REDUCING OR PREVENTING DEVELOPMENT OF SYMPTOMS OF ALCOHOL CONSUMPTION | 2022-01-27 |
20220023366 | LONICERA JAPONICA FLOWER WATER EXTRACT-CONTAINING PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HELICOBACTER PYLORI INFECTION | 2022-01-27 |
20220023367 | Botanical Antioxidants | 2022-01-27 |
20220023368 | COMPOSITION COMPRISING CHICORY ROOT AND PEA CELL WALL FIBER FOR TREATING BRACHYSPIRA INFECTIONS | 2022-01-27 |
20220023369 | METHOD OF CHINESE HERBAL MEDICINE EXTRACT USED FOR TREATING MULTIPLE DISEASES CAUSED BY DRUG RESISTANT BACTERIA INFECTION | 2022-01-27 |
20220023370 | COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES OR MENOPAUSAL SYMPTOMS | 2022-01-27 |
20220023371 | Method for Manufacturing an Ulcer Treatment | 2022-01-27 |
20220023372 | USE OF COCCULUS HIRSUTUS EXTRACT FOR TREATING DENGUE | 2022-01-27 |
20220023373 | POLYGALA EXTRACT FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER | 2022-01-27 |
20220023374 | Integrated Organism Recuperative Treatment Systems and Methods | 2022-01-27 |
20220023375 | PLANT BASED EMOLLIENT | 2022-01-27 |
20220023376 | COMPOSITIONS FOR ENHANCING BRAIN ACTIVITY | 2022-01-27 |
20220023377 | GLATIRAMER DEPOT SYSTEMS FOR TREATING PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS | 2022-01-27 |
20220023378 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING OLIGOPEPTIDE AS ACTIVE INGREDIENT | 2022-01-27 |
20220023379 | BETA-HAIRPIN PEPTIDOMIMETIC WITH ELASTASE INHIBITORY ACTIVITY AND AEROSOL DOSAGE FORMS THEREOF | 2022-01-27 |
20220023380 | COMPOSITIONS AND METHODS FOR INHIBITING INTERCELLULAR INTERACTIONS | 2022-01-27 |
20220023381 | VDAC INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | 2022-01-27 |
20220023382 | VDAC INHIBITORS FOR TREATING INFLAMMATORY BOWEL DISEASES | 2022-01-27 |
20220023383 | PHARMACEUTICAL COMPOSITIONS AND METHODS TARGETING WNT PATHWAY PROTEINS | 2022-01-27 |
20220023384 | MYBPC3 POLYPEPTIDES AND USES THEREOF | 2022-01-27 |
20220023385 | ENGINEERED FIBROBLAST GROWTH FACTOR VARIANTS COMBINED WITH ENGINEERED HEPATOCYTE GROWTH FACTOR VARIANTS FOR TREATMENT | 2022-01-27 |
20220023386 | METHOD FOR THE TREATMENT OR PREVENTION OF OSTEOARTHRITIS | 2022-01-27 |
20220023387 | PROPHYLACTIC AND THERAPEUTIC USES OF FULLY REDUCED FORMS OF HMGB1 IN CONDITIONS INVOLVING ORGANS | 2022-01-27 |
20220023388 | FUSION PROTEINS WITH EXTENDED SERUM HALF LIFE | 2022-01-27 |
20220023389 | VASODILATORS FOR USE IN THE TREATMENT OF A RETINAL ISCHEMIC DISORDER | 2022-01-27 |
20220023390 | METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | 2022-01-27 |
20220023391 | SYSTEM PROVIDING DOSE RECOMMENDATIONS FOR BASAL INSULIN TITRATION | 2022-01-27 |
20220023392 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ASPART | 2022-01-27 |
20220023393 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR SARCOPENIA, CONTAINING IF1 AS ACTIVE INGREDIENT | 2022-01-27 |
20220023394 | METHODS FOR DESENSITIZATION OF URICASE | 2022-01-27 |
20220023395 | METHODS OF TREATING OR PREVENTING CANCER WITH AN AGENT THAT DEPLETES TREGS AND A CHECKPOINT INHIBITOR | 2022-01-27 |
20220023396 | METHOD FOR IMPROVING INTESTINAL FLORA | 2022-01-27 |
20220023397 | USE OF PROUROKINASE AND ITS VARIANTS AGAINST COAGULOPATHY CAUSED BY VIRUSES | 2022-01-27 |
20220023398 | COMPOSITIONS AND METHODS FOR TREATING THYROID DISEASE | 2022-01-27 |
20220023399 | BLOOD COMPONENT POTENTIATION OF LYTIC PROTEIN ANTI-BACTERIAL ACTIVITY AND METHODS AND USES THEREOF | 2022-01-27 |
20220023400 | ARTIFICIAL PROMISCUOUS T HELPER CELL EPITOPES THAT FACILITATE TARGETED ANTIBODY PRODUCTION WITH LIMITED T CELL INFLAMMATORY RESPONSE | 2022-01-27 |
20220023401 | PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE | 2022-01-27 |
20220023402 | IMMUNOMODULATORY PHARMACEUTICAL COMPOSITIONS INCLUDING A SYNTHETIC PEPTIDE AND TRANSFORMING GROWTH FACTOR BETA | 2022-01-27 |
20220023403 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | 2022-01-27 |
20220023404 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | 2022-01-27 |
20220023405 | USE OF LEUKEMIA-DERIVED CELLS IN OVARIAN CANCER VACCINES | 2022-01-27 |
20220023406 | COMBINATION PRODUCT FOR USE IN TUMOR VACCINATION | 2022-01-27 |
20220023407 | PNEUMOCOCCAL DOSING REGIMEN | 2022-01-27 |
20220023408 | PROTECTIVE IMMUNITY ENHANCED SALMONELLA VACCINE (PIESV) AGAINST BRUCELLA SPP. | 2022-01-27 |
20220023409 | IMMUNOGENIC COMPOSITION, USE AND METHOD OF TREATMENT | 2022-01-27 |
20220023410 | CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS REPLICON PARTICLES AND USE THEREOF | 2022-01-27 |
20220023411 | INFLUENZA VACCINE | 2022-01-27 |
20220023412 | Compositions Useful in Both Homologous And Heterologous Vaccine Regimens | 2022-01-27 |
20220023413 | RECOMBINANT MUMPS VIRUS VACCINE EXPRESSING GENOTYPE G FUSION AND HEMAGGLUTININ-NEURAMINIDASE PROTEINS | 2022-01-27 |
20220023414 | Prime-Boost Vaccination Regimen | 2022-01-27 |
20220023415 | ANTI COVID-19 THERAPIES USING NUCLEOCAPSID AND SPIKE PROTEINS | 2022-01-27 |
20220023416 | VACCINE FOR PREVENTING OR TREATING CONGENITAL INFECTION WITH CYTOMEGALOVIRUS | 2022-01-27 |
20220023417 | Methods of Selecting T Cell Line and Donor Thereof for Adoptive Cellular Therapy | 2022-01-27 |
20220023418 | FUCOSYLLACTOSE AS BREAST MILK IDENTICAL NON-DIGESTIBLE OLIGOSACCHARIDE WITH NEW FUNCTIONAL BENEFIT | 2022-01-27 |
20220023419 | INHIBITING INFLAMMATION | 2022-01-27 |
20220023420 | FUSION CONSTRUCTS AND METHODS OF USING THEREOF | 2022-01-27 |
20220023421 | METHODS FOR ELICITING SELECTIVE HUMORAL RESPONSES | 2022-01-27 |
20220023422 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODY | 2022-01-27 |
20220023423 | Anti-Inflammatory Analgesic External Preparation | 2022-01-27 |
20220023424 | PEROXIDE REMOVAL FROM DRUG DELIVERY VEHICLE | 2022-01-27 |
20220023425 | STRETCHABLE BACKING LAYERS FOR TRANSDERMAL DRUG DELIVERY SYSTEMS | 2022-01-27 |
20220023426 | ORAL MUCOSAL CARRIER AND PROTECTANT | 2022-01-27 |
20220023427 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | 2022-01-27 |
20220023428 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | 2022-01-27 |
20220023429 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | 2022-01-27 |
20220023430 | GLYCOPOLYSIALYLATION OF BLINATUMOMAB | 2022-01-27 |
20220023431 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN | 2022-01-27 |
20220023432 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | 2022-01-27 |
20220023433 | Saponin Conjugates | 2022-01-27 |
20220023434 | Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods | 2022-01-27 |
20220023435 | DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES | 2022-01-27 |
20220023436 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH PARP INHIBITOR | 2022-01-27 |
20220023437 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | 2022-01-27 |
20220023438 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2022-01-27 |
20220023439 | ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF | 2022-01-27 |
20220023440 | Anti-Her2 Antibody-Maytansine Conjugates and Methods of Use Thereof | 2022-01-27 |
20220023441 | ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR | 2022-01-27 |
20220023442 | NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | 2022-01-27 |
20220023443 | DISULFIDE BOND STABILIZED POLYPEPTIDE COMPOSITIONS AND METHODS OF USE | 2022-01-27 |
20220023444 | Gene Editing-Based Method of Attenuating the Beta-Amyloid Pathway | 2022-01-27 |
20220023445 | TARGETED CONTRAST AGENTS FOR MRI OF AMYLOID DEPOSITION | 2022-01-27 |
20220023446 | MAGNETIC TRACER COMPOSITIONS | 2022-01-27 |
20220023447 | FIBRIN-TARGETED POLYMERIZED SHELL LIPID MICROBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | 2022-01-27 |
20220023448 | DENDRIMER FOR THERAPY AND IMAGING | 2022-01-27 |
20220023449 | PHARMACEUTICAL PREPARATION | 2022-01-27 |
20220023450 | BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USE | 2022-01-27 |
20220023451 | METHOD FOR STERILIZING FLEXIBLE BAGS | 2022-01-27 |
20220023452 | AQUEOUS OZONE SANITIZING SYSTEM CONTROLLER AND METHODS | 2022-01-27 |
20220023453 | HAND SANITIZING AQUEOUS OZONE SPRAY CHAMBER | 2022-01-27 |
20220023454 | PHOTODYNAMIC METHOD TO DECONTAMINATE SURFACES | 2022-01-27 |
20220023455 | PORTABLE SANITIZATION SYSTEM AND METHOD WITH ULTRAVIOLET AND VISIBLE LIGHT SENSING | 2022-01-27 |
20220023456 | UV SANITIZING LIGHT MODULE AND CONTAINER SYSTEM | 2022-01-27 |
20220023457 | MODULAR APPARATUS WITH UNIVERSAL BASE FRAME FOR ULTRAVIOLET (UV) LIGHT SANITIZATION OF AN AIRCRAFT AND METHODS FOR PRODUCING SAME | 2022-01-27 |
20220023458 | PORTABLE SANITIZING SYSTEMS AND METHODS | 2022-01-27 |
20220023459 | ULTRAVIOLET LIGHT SANITIZING CART | 2022-01-27 |
20220023460 | WATERPROOF DISINFECTION LAMP | 2022-01-27 |
20220023461 | STERILIZATION DEVICE WITH DOSE FUNCTION | 2022-01-27 |